Polymorphism at P21 codon 31 and dinucleotide polymorphism of P73 gene and susceptibility to bladder cancer in individuals from North India

Jaiswal, Praveen Kumar; Singh, Vibha; Mittal, Rama Devi
September 2013
Indian Journal of Human Genetics;Jul-Sep2013, Vol. 19 Issue 3, p293
Academic Journal
BACKGROUND AND AIM: p73, a novel P53 homolog and plays an important role in modulating cell cycle control, apoptosis and cell growth while P21, functions to negatively control the cell cycle. P53 up regulates p21 expression in response to deoxyribonucleic acid damage leading to cell cycle arrest at G1 checkpoint. In the present study, we are targeting p21 codon 31 and p73 gene variants of G4C14-to-A4T14 (Exon 2) polymorphism for bladder cancer (BC) risk in North Indians. MATERIALS AND METHODS: The above gene variants of P21 and P73 were assessed in the case-control study comprising of 200 BC cases and 200 healthy controls of the same age, gender and similar ethnicity. Genotyping was performed by polymerase chain reaction (PCR) restriction fragment length polymorphism method and PCR-based confronting two-pair primers (PCR with CTPP). RESULTS: The variant genotype of p73Exon 2 polymorphism showed significant risk for BC (p = 0.014). While combining with heterozygous genotype, variant genotype of p73Exon2 showed a significant association with BC risk (p = 0.010). While in case of p21 codon31 showed no significant association for BC risk at genotypic level. Significant association between p73Exon2 polymorphism and smoking was observed for BC risk. Furthermore, gene combination analysis revealed that AT/AT-Ser/Ser is associated with risk for BC. Variant genotype of P73Exon2 was associated with reduced risk of recurrence (p = 0.039) in superficial BC patients receiving Bacillus Calmette-Guerin treatment thus showing least survival (log rank = 0.029). CONCLUSION: Our study provided evidence that the p73 G4C14 > A4T14 (Exon2) polymorphisms were associated with higher risk of BC in North Indian population.


Related Articles

  • Results of second transurethral resection for high-grade T1 bladder cancer. Katsuyoshi Hashine; Takehiro Ide; Takeshi Nakashima; Tadanori Hosokawa; Iku Ninomiya; Norihiro Teramoto // Urology Annals;Jan-Mar2016, Vol. 8 Issue 1, p10 

    Background: The aim of this study was to examine the histological outcome and potential therapeutic benefit of second transurethral resection (TUR) for high-grade T1 bladder cancer. Patients and Methods: The subjects were 171 patients who underwent initial TUR between January 1993 and December...

  • BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients. Hmeljak, Julija; Erčulj, Nina; Dolžan, Vita; Kern, Izidor; Cör, Andrej // Journal of Cancer Research & Clinical Oncology;Nov2011, Vol. 137 Issue 11, p1641 

    Purpose: Malignant pleural mesothelioma is an incurable, asbestos-associated cancer. Its incidence is rapidly increasing and survival remains short. Apoptosis deregulation is an important feature of cancer and survivin, a member of the inhibitor-of-apoptosis-protein family encoded by the BIRC5...

  • A novel survival multifactor dimensionality reduction method for detecting gene-gene interactions with application to bladder cancer prognosis. Jiang Gui; Moore, Jason H.; Kelsey, Karl T.; Marsit, Carmen J.; Karagas, Margaret R.; Andrew, Angeline S. // Human Genetics;Jan2011, Vol. 129 Issue 1, p101 

    The widespread use of high-throughput methods of single nucleotide polymorphism (SNP) genotyping has created a number of computational and statistical challenges. The problem of identifying SNP-SNP interactions in case-control studies has been studied extensively, and a number of new techniques...

  • Association of Selected Variants in Genes Involved in Cell Cycle and Apoptosis with Bladder Cancer Risk in North Indian Population. Gangwar, Ruchika; Mittal, Rama Devi // DNA & Cell Biology;Jul2010, Vol. 29 Issue 7, p349 

    Perturbations in the cell cycle and apoptotic genes have been implicated in human malignancies. Cell cycle ( MDM2 and Cyclin D1) and apoptotic ( Fas) genes that are differentially expressed in urinary bladder cancer (UBC) were investigated with the susceptibility to UBC in northern India. A...

  • MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Paule, Bernard; Castagne, Vincent; Picard, Véronique; Saffroy, Raphaël; Adam, René; Guettier, Catherine; Farinotti, Robert; Bonhomme-Faivre, Laurence // Medical Oncology;Dec2010, Vol. 27 Issue 4, p1066 

    The aim of the study was to evaluate the influence of the MDR1 C3435T polymorphism on the therapeutic response in 23 patients treated with cetuximab plus irinotecan for irinotecan refractory liver metastatic colorectal cancer considering their KRAS status. Indeed, irinotecan and its active...

  • The increase in bladder carcinoma cell population induced by the free beta subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation. Butler, S A; Ikram, M S; Mathieu, S; Iles, R K // British Journal of Cancer;5/1/2000, Vol. 82 Issue 9, p1553 

    Ectopic production of free beta human chorionic gonadotrophin (hCGβ) by bladder carcinoma is well described and occurs in approximately 35% of cases. hCGβ secreting tumours are more aggressive, radioresistant and have a greater propensity to metastasize. We proposed that the ectopic...

  • BCG spares bladder in high-risk superficial cancer. Prescott, Lawrence M. // Urology Times;Sep2001, Vol. 29 Issue 9, p11 

    Examines the use of bacillus Calmette-Guerin as treatment for high-risk superficial bladder cancer in Anaheim, California. Survival rate of the patient; Risk associated with superficial bladder cancer; Response of patients after initial therapy.

  • Use of bacille Calmette-Guérin in superficial bladder cancer. Meyer, J.-P.; Persad, R.; Gillatt, D.A. // Postgraduate Medical Journal;Aug2002, Vol. 78 Issue 922, p449 

    Intravesical bacille Calmette-Guérin (BCG) has been used by urologists for several years after its first reported use as a cancer therapy in the 1930s. Morales in 1976 described the usage of BCG as a once weekly intravesical instillation for six weeks; this is a treatment regimen that still...

  • BCG vaccine in superficial bladder cancer. Sharma, Neeraj; Prescott, Stephen // BMJ: British Medical Journal (International Edition);3/26/94, Vol. 308 Issue 6932, p801 

    Ermines the effectiveness of BCG vaccine for treating superficial bladder cancer in Great Britain. Factors of increasing the risk of progression; Observations of using BCG vaccine for diffuse carcinoma in situ; Comparison between BCG vaccine and intravesical chemotherapeutic agents.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics